The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer-Reference-Cited by-同舟云学术

The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer

Published:2022-06 Issue:6 Volume:33 Page:593-601
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Francis K.E.,Kim S.I.,Friedlander M.,Gebski V.,Ray-Coquard I.,Clamp A.,Penson R.T.,Oza A.,Perri T.,Huzarski T.,Martin-Lorente C.,Cecere S.C.,Colombo N.,Ataseven B.,Fujiwara K.,Sonke G.,Vergote I.,Pujade-Lauraine E.,Kim J.-W.,Lee C.K.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference29 articles.

1. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial;Pujade-Lauraine;Lancet Oncol,2017

2. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial;Poveda;Lancet Oncol,2021

3. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer;Moore;N Engl J Med,2018

4. The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients;Qi;Sci Rep,2020

5. A review of relative dose intensity and survival in patients with metastatic solid tumors;Havrilesky;Crit Rev Oncol Hematol,2014

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined aqupla, paclitaxel liposome, and docetaxel treatment: survival and biomarker outcomes in recurrent ovarian cancer patients;Frontiers in Oncology;2024-06-17

2. Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients;International Journal of Gynecologic Cancer;2024-06-10

3. To modulate or to skip: De-escalating PARP inhibitor maintenance therapy in ovarian cancer using adaptive therapy;Cell Systems;2024-06

4. Olaparib maintenance therapy for platinum‐sensitive relapsed ovarian cancer at a single institution: A retrospective study;Journal of Obstetrics and Gynaecology Research;2024-05-14

5. Predictors of olaparib discontinuation owing to adverse drug events in patients with ovarian, peritoneal, or fallopian tube cancer: a retrospective observational study;Journal of Chemotherapy;2024-05-02